BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of Natasha Hernday as Vice President, Corporate Development. Ms. Hernday brings 10 years of experience in business and corporate development, including in-licensing, out-licensing and mergers and acquisitions. In addition, the company announced the promotion of Eric Sievers, M.D., to Vice President, Clinical Affairs. Dr. Sievers joined Seattle Genetics in 2006, and has played a key leadership role in the company’s brentuximab vedotin (SGN-35) program, including the recent Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA).
